Business Wire

Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira® (adalimumab)

Jaa

Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced the company will partner with Mylan N.V. (NASDAQ:MYL) to commercialize FKB327, a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics. It has entered into an agreement with Mylan to grant an exclusive commercialization right of FKB327 in Europe.

Humira is a TNF-α1 inhibitor aimed at treating multiple chronic inflammatory conditions. The product is indicated in Europe for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis. Humira is the world’s best-selling biologic medication and had brand sales of approximately $4.1 billion in Europe for the 12 months ending Dec. 31, 2017, according to IQVIA.

“I am delighted that we entered into partnership with Mylan for an adalimumab biosimilar, FKB327 in Europe," said Dr. Yoshifumi Torii, President and CEO of Fujifilm Kyowa Kirin Biologics. “I believe that the establishment of this agreement with Mylan attests to the value of Fujifilm Kyowa Kirin Biologics' proprietary technology in biosimilars space and Mylan’s significant experience and expertise in regulatory commercialization with Fujifilm Kyowa Kirin Biologics’ scientific expertise will ensure patients across Europe benefit from the treatment option.”

Under the terms of the agreement between two companies, Fujifilm Kyowa Kirin Biologics grants Mylan an exclusive license to commercialize FKB327 in Europe and will receive an up-front fee. In addition, Fujifilm Kyowa Kirin Biologics is eligible to receive a subsequent commercialization milestone payment and sales royalties. Mylan will be responsible for the sales activity of the product in European countries.

The two companies continue to negotiate for commercializing the product in additional territories.

The European Medicines Agency (EMA) accepted for review the Marketing Authorisation Application for its proposed biosimilar to Humira on May 18, 2017. The companies expect to receive a decision from EMA in the second half of 2018.

Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation (President: Kenji Sukeno; hereinafter “Fujifilm”) and Kyowa Hakko Kirin Co., Ltd. (President and COO: Masashi Miyamoto, hereinafter “Kyowa Hakko Kirin”) on March 27, 2012 as a company for developing, manufacturing, and marketing biosimilars. Its pipeline includes an adalimumab biosimilar and a biosimilar of the anti-VEGF humanized monoclonal antibody bevacizumab (Development No. FKB238), a drug used to treat a range of cancers including colorectal and non-small cell lung cancer. Fujifilm Kyowa Kirin Biologics established Centus Biotherapeutics Ltd., a joint venture for the development and commercialization of FKB238 with AstraZeneca plc.

By merging the technologies in advanced production, quality control and analysis which Fujifilm has developed over many years through its photographic film business, with the proprietary technologies and know-how which Kyowa Hakko Kirin has accumulated through its biopharmaceutical R&D and manufacturing, Fujifilm Kyowa Kirin Biologics creates revolutionary production processes and reduces costs for the production of biosimilars. Through this partnership, the company will develop and manufacture reliable, high quality, cost-competitive biosimilar products and commercialize these products in a timely manner. With this strategy, Fujifilm Kyowa Kirin Biologics aims to hold a leading position in the expanding biosimilar market.

1 TNF-α (tumor necrosis factor alpha) is a cytokine that is involved in inhibition of tumorigenesis and defense against infection. Overexpression of TNF-α is implicated in a range of inflammatory diseases, including rheumatoid arthritis and psoriasis.

Contact information

FUJIFILM Corporation
Kana Matsumoto, +81-3-6271-2000
Corporate Communications Division
or
Kyowa Hakko Kirin Co., Ltd.
Hiroki Nakamura
Corporate Communications Department
media@kyowa-kirin.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Servier and Taiho Announce Phase III Trial Data Demonstrates Significant Overall Survival Benefit of LONSURF® (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer21.6.2018 14:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced clinical data from the pivotal Phase III trial (TAGS) for LONSURF® (trifluridine and tipiracil, TAS-102) which showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC 0.56-0.85], p=0.0003). The median overall survival in patients treated with trifluridine/tipiracil and best supportive care (BSC) was 5.7 months as compared to 3.6 months when treated with placebo and BSC, and they had a 31% risk reduction of death. At 12-months, OS rates were 21.2% in the trifluridine/tipiracil group and 13.0% in the placebo group. In addition, the risk for disease progression measured by PFS, a key secondary endpoint, was reduced by 43% (HR: 0.57). The overall safety profile was consistent with the known safety profile of trifluridine/tipiracil in metastatic colorectal cancer (CRC), with mainly hematological adverse events reported. “The results presented to

SimScale Announces a Preview Program of FDS for Simulation of Fire Scenarios in Buildings21.6.2018 13:49Tiedote

SimScale (“SimScale”), the provider of the world’s first cloud-based engineering simulation solution, today announced the launch of the Fire Dynamics Simulator (FDS) explorative preview program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005523/en/ Fire Dynamics Simulator (FDS) is a solver developed by the National Institute of Standards and Technology (NIST) of the United States Department of Commerce, in cooperation with VTT Technical Research Centre of Finland. Throughout its development, FDS has been aimed at solving practical fire problems in fire protection engineering, while at the same time providing a tool to study fundamental fire dynamics and combustion. The preview program is a response to the request of many customers to combine the maturity and reliability of FDS for modeling fire and smoke with the convenience and scalability of SimScale’s cloud-based simulation infrastructure. Most of these requests

Warehouse TERRADA Forms a Three-Party Partnership with Yokohama University of Art and Design and PALAZZO SPINELLI, an Italian Institute for Art and Restoration21.6.2018 12:00Tiedote

Warehouse TERRADA formed a three-party partnership with Tokiwamatsu Gakuen’s Yokohama University of Art and Design and PALAZZO SPINELLI ISTITUTO PER L’ARTE E IL RESTAURO, an institute for art and restoration located in Florence, Italy, concerning the restoration and preservation of cultural heritage in Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005372/en/ From left) Emanuele Amodei, President of Palazzo Spinelli / Yasuyuki Korekawa, Operating officer of Warehouse TERRADA / Nobuaki Okamoto, Chairman of the Board of Directors, Tokiwamatsu Gakuen and President, Yokohama University of Art and Design (Photo: Business Wire) Warehouse TERRADA has always considered it to be important to educate future professionals involved in the restoration and preservation of artworks and craftworks. We have made a wide-ranging proactive effort in this field, such as by launching a collaborative course in art restoration and pres

Further STAC Approval for Smiths Detection’s Checkpoint.Evoplus21.6.2018 11:00Tiedote

The latest version of Smiths Detection’s Checkpoint.Evoplus software has been certified by STAC for use at French airports. Version 2.2. has followed in the footsteps of 2.1, which was the first ever solution for multiplexed image analysis to receive official approval from the French civil aviation authority technical centre. An advanced screening and management platform, Checkpoint.Evoplus is designed to increase passenger throughput; optimise resources; reduce operational costs; and raise security levels. “Both versions of Checkpoint.Evoplus have now gained STAC certification –further approval for a very innovative platform, which continues to set the standards for checkpoint management software,” commented Matt Clark, VP Technology & Product Development, Smiths Detection. “It holds the key to ensuring that checkpoints can reach their full potential by delivering the highest levels of security and also significant operational advances.” Checkpoint.Evoplus transforms a collection of i

Presidentti Obama Nordic Business Forumiin Helsinkiin21.6.2018 10:59Tiedote

Yhdysvaltain entinen presidentti Barack Obama on kiinnitetty puhumaan Nordic Business Forumissa, joka järjestetään 26.-27.9.2018 Helsingissä. Presidentti Obama tulee päättämään kaksipäiväisen tapahtuman. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180621005425/fi/ Europe’s leading business and leadership conference brings President Obama to Helsinki, Finland to speak to business executives and owners. (Photo: Business Wire) Aslak de Silva, Nordic Business Forumin toimitusjohtaja: “Tämä on meille valtava kunnia, ja myös hieno mahdollisuus ja tilaisuus asiakkaillemme sekä Suomelle ja Pohjoismaille.” Hans-Peter Siefen, Nordic Business Forum hallituksen puheenjohtaja ja perustajajäsen: “Todella hienoa saada presidentti Obama tapahtumamme pääpuhujaksi. Tapahtuman agenda on jo ennestään upea ja tämä on sille hieno kruunu. Varmasti merkittävin puhujakiinnityksemme koskaan. Pari muutakin hyvin teemaspesifiä puhujaa on vielä tu

Mori Building and teamLab Launch Unprecedented Digital Art Museum21.6.2018 05:00Tiedote

“MORI Building DIGITAL ART MUSEUM: teamLab Borderless,” an unprecedented digital art museum — jointly created and operated by Mori Building Co., Ltd, a leading urban landscape developer, and teamLab, a world-leading digital art collective — opened today, the two organizers announced. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180620005005/en/ Toshiyuki Inoko, Founder of teamLab (Photo: Business Wire) The digital art museum features approximately 50 interactive artworks, some completely new, in a huge 10,000m² area with five zones. The interactive artworks have no borders separating them from the other works. Some extend beyond their installation rooms and into the corridors, some overlap with other works and some even fuse with other works. Since there are no boundaries, the immersive works keep the boundaries between people in a state of continuous flux. Visitors physically enter and explore the works as well as experie

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme